Diagnostic Products Corporation launches three assays for Immulite 2000:
This article was originally published in Clinica
Executive Summary
Diagnostic Products Corporation is launching two assays for the assessment of thyroid status and one to monitor therapy in epithelial ovarian cancer. All three run on DPC's Immulite 2000 analyser. One of the thyroid assays offers quantitative measurement of thyrotropin (TSH) in serum, while the other quantitatively assesses free, uncomplexed triiodothyronine (T3) in serum. The third assay from Los Angeles-based DPC is a quantitative CA125 antigen in serum.